Replimune's Double-Edged Victory: FDA Approval Arrives With a Lawsuit in the Wings

Replimune's TUDRIQEV wins FDA accelerated approval, doubling shares, yet class action, SEC inquiry, and high volatility temper the bullish outlook.

The approval that Replimune spent years chasing arrived on August 6, when the FDA granted accelerated clearance for TUDRIQEV in combination with nivolumab for advanced, inoperable melanoma that has progressed despite anti-PD-1 therapy. Yet the milestone has landed the company in an unusual position: celebrating a regulatory win while simultaneously defending the very data that underpins it.

That tension is now the defining feature of the stock's trading pattern. Replimune shares have roughly doubled over the past month, with the 30-day gain standing at 51 percent. But the annualized volatility of 347 percent tells a more complicated story — one in which a class action lawsuit, a lingering SEC inquiry, and the memory of two Complete Response Letters all compete with the commercial promise of a newly approved oncology product.

The Bull Case Is Built on Execution

On the operational front, the company has moved with purpose since the approval landed. A capital raise completed August 11 brought in roughly $141.0 million through the sale of 9,701,490 shares at $12.06 each, supplemented by pre-funded warrants. Combined with cash and short-term investments of $195.3 million as of June 30, management says the balance sheet now supports more than twelve months of runway.

The first fiscal quarter results, reported August 14, showed a narrowing net loss of $69.8 million versus $86.7 million in the prior-year period. Research and development spending came in at $49.3 million, while selling costs totaled $19.0 million — both down from previous levels.

A week later, the company installed Michelle DiNapoli as chief commercial officer, a hire whose 25-plus years in oncology commercialization suggests the launch is being taken seriously. TUDRIQEV is expected to hit the U.S. market within 60 days of approval.

Analysts have responded in kind. Wedbush Securities raised its price target to $19 from $12 on August 7 and upgraded the stock to Outperform. BMO Capital Markets followed the same day, lifting its target to $20 from $16. The revisions reflect a consensus that the commercial opportunity is now far larger than the market appreciated earlier in the summer.

The Clinical Record, Both Strong and Complicated

The efficacy data that secured the approval are genuinely notable. In the pivotal phase 3 trial, roughly one-third of patients who had stopped responding to anti-PD-1 therapies saw their tumors shrink when treated with the combination. In cutaneous squamous cell carcinoma, the complete response rate reached approximately 50 percent when paired with nivolumab, and median overall survival stretched to 32.9 months over a three-year horizon.

The approval has also cast a favorable light on the broader class of oncolytic viruses. South Korea's Sillajen saw double-digit gains on Wednesday as investors read the FDA's decision as validation for the entire modality.

An upcoming ODAC meeting on RP1 could provide further regulatory clarity for additional indications, potentially supporting a re-rating of the platform itself.

The Legal Overhang That Won't Go Away

But the approval story has a shadow. A securities class action filed August 17 alleges that Replimune failed to disclose concerns about the trial design — specifically, that an unplanned interim analysis was submitted with only 40 of a planned 400 patients, and that deficiencies in that submission made an FDA rejection likely. The lawsuit covers the period from October 2025 through April 2026, when the company is accused of making false statements regarding its Biologics License Application.

The FDA did reject the original application in April, sending the stock from roughly $10.86 down to $4.76. A second Complete Response Letter followed, and it was only the second resubmission that ultimately succeeded.

The fact that approval was eventually granted does not neutralize the lawsuit, which concerns disclosure obligations during the earlier period rather than the final outcome. A separate SEC investigation remains open, with the company having already produced documents. The defense was required to respond to a second amended complaint on August 17, following the April CRL.

Investors have until October 5 to join the action as lead plaintiffs — a date that could surface new details about the case and management's risk assessment.

Insider Sales Add a Footnote

CEO Sushil Patel sold 39,341 shares on August 10, a transaction the company characterizes as a tax-driven "sell-to-cover" exercise related to vesting restricted stock units. Insider Konstantinos Xynos also disposed of 11,447 shares, valued at roughly $148,468. Neither sale appears to signal a loss of confidence, but they add another layer of scrutiny to a stock already under the microscope.

What Comes Next

The immediate path forward hinges on the commercial rollout. A smooth launch with no major setbacks and no fresh negative developments in the litigation would likely allow the recovery trend to continue — albeit with the violent swings that have become Replimune's trademark.

The risks are equally visible. The class action could prove costly regardless of its outcome, through legal fees alone and the chilling effect on institutional interest. The Ultragenyx situation — where a gene therapy decision has already slipped — serves as a reminder that FDA timelines remain unpredictable, a pattern Replimune knows intimately from its own two CRLs.

With the RSI at 65.4, the recent rally is already showing signs of being stretched. Should the market's perception shift — through new allegations, a sluggish launch, or disappointing early sales data — the gains of the past month could evaporate quickly.

For now, the bulls have the more concrete evidence: approval, financing, and management building are all documented and verifiable. But the legal chapter remains unwritten, and the October 5 lead plaintiff deadline looms as the next catalyst. Investors willing to hold this stock must be prepared for the volatility that comes with a story that is only half told.